Revolution Medicines/$RVMD
1D1W1MYTD1Y5YMAX
Capital at risk
About Revolution Medicines
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.
- Ticker
- $RVMD
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 883
- Headquarters
- Redwood City, United States
- Website
- www.revmed.com
RVMD Metrics
BasicAdvanced
$44B
-
-$8.92
1.40
-
Price and volume
Market cap
$44B
Beta
1.4
52-week high
$224.31
52-week low
$42.18
Average daily volume
1.7M
Financial strength
Current ratio
11.378
Quick ratio
11.122
Long term debt to equity
0.45
Total debt to equity
0.457
Interest coverage (TTM)
-27.42%
Profitability
EBITDA (TTM)
-1,618.188
Management effectiveness
Return on assets (TTM)
-30.12%
Return on equity (TTM)
-79.09%
Valuation
Price to book
16.86
Price to tangible book (TTM)
17.33
Price to free cash flow (TTM)
-32.996
Free cash flow yield (TTM)
-3.03%
Free cash flow per share (TTM)
-6.216
Growth
Earnings per share change (TTM)
97.14%
3-year earnings per share growth (CAGR)
41.44%
What the Analysts think about RVMD
Analyst ratings (Buy, Hold, Sell) for Revolution Medicines stock.
Analyst projections of the future price of Revolution Medicines stock.
Bulls say / Bears say
FDA approval of daraxonrasib (RASONQUE) on August 26, 2026 marks the first broad RAS-targeted therapy cleared for metastatic pancreatic cancer, validating Revolution Medicines’ platform (FDA).
The pivotal Phase 3 RASolute 302 trial showed an overall survival hazard ratio of 0.49 versus chemotherapy, nearly doubling median survival and underscoring daraxonrasib’s clinical efficacy (FDA).
A $2 billion non-dilutive funding agreement with Royalty Pharma, including a $750 million senior secured loan and up to $1.25 billion in synthetic royalties, secures runway through regulatory milestones and commercialization (SEC 8-K).
High operating cash burn with R&D expenses of $344 million in Q1 2026 and full-year GAAP operating expense guidance of $1.7 to 1.8 billion suggests significant cash burn ahead of meaningful revenue generation (Revolution Medicines Q1 2026 Report).
Despite approval, daraxonrasib’s median progression-free survival improvement of 7.2 months versus 3.6 months may limit peak market uptake amid reimbursement scrutiny and competitive RAS-targeting entrants (FDA).
Next major clinical catalyst from non-pancreatic programs is a RASolve 301 NSCLC readout not expected until 2027, creating a prolonged valuation gap absent near-term data from other pipeline assets (Revolution Medicines Q2 2026 Report).
Data summarised monthly by Lightyear AI. Last updated on 28 Aug 2026.
RVMD Financial Performance
Revenues and expenses
RVMD Earnings Performance
Company profitability
Upcoming events
No upcoming events
RVMD News
AllArticlesVideos
Funds containing RVMD
AllUSDGBPEUR
Fund name | Fund size | $RVMD weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 2.74% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 2.74% |
Xtrackers S&P 500 Swap£XSPX | £3.1B | 0.33% |
iShares MSCI USA ESG Enhanced€OM3L | €16B | 0.10% |
iShares MSCI USA CTB Enhanced ESG£EEDG | £14B | 0.10% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.